|Bid||2.6700 x 1300|
|Ask||2.7400 x 1200|
|Day's Range||2.6100 - 2.8102|
|52 Week Range||1.2600 - 6.7500|
|Beta (5Y Monthly)||2.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secur
Shareholders of ASLAN Pharmaceuticals (NASDAQ: ASLN) are primed for a good weekend. Raycroft believes the shares are worth $8 apiece, more than 150% higher than Thursday's closing price. ASLAN, a clinical-stage immunology biotech, only has two treatments in development.
'ASLN's '004 is a fast follower, targeting an understood, de-risked path in atopic dermatitis [eczema],' said Jefferies analyst Maury Raycroft.